Somashekhar M. Metri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Somashekhar M. Metri has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Agasa Ramu Mahesh
Department of Pharmaceutical Chemistry, The Oxford College of Pharmacy, Bengaluru, Karnataka, India
1 shared publication - Akila Elias
Department of Pharmacognosy Al‐Ameen College of Pharmacy Bangalore India
1 shared publication - Aleesha Mujeeb Shaheen
Department of Pharmaceutical Chemistry Al‐Ameen College of Pharmacy Bengaluru India
1 shared publication - Bipindra Pandey
Department of Pharmacy, Madan Bhandari Academy of Health Sciences, Hetauda 44107, Nepal
1 shared publication - Chanda Ranjan
Department of Pharmaceutical Chemistry, The Oxford College of Pharmacy, Bengaluru, Karnataka, India
1 shared publication - Deepti Pandey
Department of Pharmacy Universal College of Medical Sciences Bhairahawa Nepal
1 shared publication
Latest Publications
- 25 September 2026
- Published by Bentham Science Publishers Ltd. in Current Advances in Medicine
- Vol. 02 (1) , 1-17
Phytochemical Horizons in Anticancer Drug Discovery: From Lead Molecules to Clinical Prospects
In the present day, there is a great concern about the second deadliest disease, cancer. An enormous number of mortalities rate is increasing every year because of cancer despite a few inter-cessions accessible. Advancements in potency with fewer side effects make anticancer treatment a promising area of drug development. Phytochemicals can be potent in this manner. These bioactive natural products are unique and target malignant cells differentially, with little alteration in normal cells. Phytochemicals exhibit pleiotropic activity and, more specifically, are among the most promis-ing candidates for advanced cancer therapy. This chapter summarises the various lead anticancer phytochemicals and the complex drug development processes associated with natural products. We discuss the specific challenges encountered during the discovery and development of anti-malignant phytochemicals, as well as the current clinical landscape. By examining successful transitions of dif-ferent phytochemicals from lead molecules to clinical candidates, this review highlights the scope and potential of plant-derived compounds in revolutionising the treatment of cancer. This review highlights the scope and potential of plant-derived compounds to revolutionise cancer treatment.
- 25 September 2026
- Published by Bentham Science Publishers Ltd. in Current Advances in Medicine
- Vol. 02 (1) , 1-17
Phytochemical Horizons in Anticancer Drug Discovery: From Lead Molecules to Clinical Prospects
In the present day, there is a great concern about the second deadliest disease, cancer. An enormous number of mortalities rate is increasing every year because of cancer despite a few inter-cessions accessible. Advancements in potency with fewer side effects make anticancer treatment a promising area of drug development. Phytochemicals can be potent in this manner. These bioactive natural products are unique and target malignant cells differentially, with little alteration in normal cells. Phytochemicals exhibit pleiotropic activity and, more specifically, are among the most promis-ing candidates for advanced cancer therapy. This chapter summarises the various lead anticancer phytochemicals and the complex drug development processes associated with natural products. We discuss the specific challenges encountered during the discovery and development of anti-malignant phytochemicals, as well as the current clinical landscape. By examining successful transitions of dif-ferent phytochemicals from lead molecules to clinical candidates, this review highlights the scope and potential of plant-derived compounds in revolutionising the treatment of cancer. This review highlights the scope and potential of plant-derived compounds to revolutionise cancer treatment.
- 17 April 2026
- Published by Elsevier
- p. 27-48
Nanotechnology in gamete health: Improving egg and sperm viability
- 17 April 2026
- Published by Elsevier
- p. 27-48
Nanotechnology in gamete health: Improving egg and sperm viability
- 17 April 2026
- Published by Elsevier
- p. 129-152
Nanotechnology in follicle tracking and ovarian stimulation
- 17 April 2026
- Published by Elsevier
- p. 129-152
Nanotechnology in follicle tracking and ovarian stimulation
- Open Access
- 11 November 2025
- Published by Wiley in Food Science & Nutrition
- Vol. 13 (11)
Phytochemical Profile and α‐Amylase Inhibitory Activity of Pomegranate Peel Extract: An In Silico and In Vitro Investigation
Diabetes is among the top ten causes of mortality and morbidity. Diabetes has been increasing faster in low‐ and middle‐income nations than it has been rising in high‐income countries. This study explores the phytochemical profiling and in vitro α‐amylase inhibitory activity of the methanolic extract of Nepalese‐origin pomegranate peels. Phytochemical analysis using FT‐IR and LC–MS identified key bioactive compounds, including ellagic acid, punicalagin, punicalin, gallic acid, and ellagic acid‐O‐xylopyranoside, contributing to the observed enzymatic inhibition. Molecular docking studies revealed strong binding affinities of punicalagin (−11.6 kcal/mol) and ellagic acid‐O‐xylopyranoside (−10.6 kcal/mol) to α‐amylase, suggesting potential antidiabetic properties. MD simulations confirmed the stability of these interactions over a 100 ns timeframe, reinforcing their role in enzyme inhibition. The in vitro α‐amylase inhibition assay demonstrated comparable activity of pomegranate peel extract (IC 50 = 137.74 μg/mL) to reference drug acarbose (IC 50 = 222.19 μg/mL). These findings provide molecular insights into the bioactivity of pomegranate peel extracts, highlighting their potential in diabetes management.
- 11 November 2025
- Published by Wiley in Food Science & Nutrition
- Vol. 13 (11)
Open AccessPhytochemical Profile and α‐Amylase Inhibitory Activity of Pomegranate Peel Extract: An In Silico and In Vitro Investigation
Diabetes is among the top ten causes of mortality and morbidity. Diabetes has been increasing faster in low‐ and middle‐income nations than it has been rising in high‐income countries. This study explores the phytochemical profiling and in vitro α‐amylase inhibitory activity of the methanolic extract of Nepalese‐origin pomegranate peels. Phytochemical analysis using FT‐IR and LC–MS identified key bioactive compounds, including ellagic acid, punicalagin, punicalin, gallic acid, and ellagic acid‐O‐xylopyranoside, contributing to the observed enzymatic inhibition. Molecular docking studies revealed strong binding affinities of punicalagin (−11.6 kcal/mol) and ellagic acid‐O‐xylopyranoside (−10.6 kcal/mol) to α‐amylase, suggesting potential antidiabetic properties. MD simulations confirmed the stability of these interactions over a 100 ns timeframe, reinforcing their role in enzyme inhibition. The in vitro α‐amylase inhibition assay demonstrated comparable activity of pomegranate peel extract (IC 50 = 137.74 μg/mL) to reference drug acarbose (IC 50 = 222.19 μg/mL). These findings provide molecular insights into the bioactivity of pomegranate peel extracts, highlighting their potential in diabetes management.